Key result
Aspirin use at presentation neither decreased pulmonary artery thrombus burden nor improved short-term mortality in 398 patients with acute pulmonary embolism.
Why the study?
Despite widespread use of anticoagulants for venous thromboembolism, there is an ongoing belief that platelet reactivity contributes to thrombus burden in acute pulmonary embolism.
Does anti-platelet medication use at presentation improve PA thrombus burden, RV load, or short-term mortality in patients with acute pulmonary embolism?
Observational (n=398)
Does anti-platelet medication use at presentation improve PA thrombus burden, RV load, or short-term mortality in patients with acute pulmonary embolism?
Anti-platelet therapy (mostly aspirin) at presentation does not appear to reduce thrombus burden or improve short-term mortality in patients with acute pulmonary embolism.
Answers are grounded in this paper and cite their sources.
Should not alter acute PE management; leaves open antiplatelet effects on thrombus burden in prospective cohorts.
Venous thromboembolism (VTE) whether provoked or not can be life-threatening due to an acute increase in load on the right ventricle (RV) from obstruction of the pulmonary artery (PA). Treatment for and prevention of VTE involves anti-thrombotic agents; more specifically, medications targeting the anticoagulation cascade. In spite of the widespread acceptance of anticoagulants in the treatment of VTE, there appears to be an ongoing belief that platelet reactivity contributes to thrombus burden in patients with acute pulmonary embolism (PE). This investigation of 398 patients presenting with acute PE evaluated whether anti-platelet medication use, which consisted mostly of aspirin therapy, at the time of presentation, affects PA thrombus burden, RV load, or short-term patient outcomes. We conclude that platelets may have been erroneously incriminated as direct thrombotic mediators in patients with acute PE since aspirin neither decreased PA thrombus burden, nor did aspirin improve short-term mortality following acute PE.
No takes yet. Share an insight, caveat, or question.
Galen et al. (2020) conducted an observational in Acute pulmonary embolism (n=398). Anti-platelet medication (mostly aspirin) vs. No anti-platelet medication was evaluated on Pulmonary artery thrombus burden, right ventricular load, and short-term mortality. Aspirin use at presentation neither decreased pulmonary artery thrombus burden nor improved short-term mortality in 398 patients with acute pulmonary embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: